Uncomplicated Acute Appendicitis
4
0
0
0
Key Insights
Highlights
Treatment Research
5 treatments under study, led by Ketorolacgrindeks 30 Mgml Šķīdums Injekcijām
Research Leaders
11 sponsors active, led by Hospital Universitario Virgen de la Arrixaca
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 4 trials
25%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (4)
Oral Antibiotic Outpatient Therapy vs. Placebo in the Treatment of Uncomplicated Acute Appendicitis
Clinical Pathway With "Fast-Track" In Uncomplicated Acute Appendicitis
Oral Antibiotic Outpatient Therapy vs. Placebo in the Treatment of Uncomplicated Acute Appendicitis
“Study of pain syndrome and clinical-biochemical parameters in children aged 7 to 18 years in cases of non-surgical treatment of uncomplicated acute appendicitis”
Research Network
Common Treatments
- Ketorolacgrindeks 30 Mgml Šķīdums Injekcijām1
- Active Investigational Medicinal Product Imp Contains 400 Mg Of Moxifloxacin 1 X 400 Mg Tablet Moxifloxacin 400 Mg Tablets Which Are Authorized Medicinal Products Are Sourced From Legal Supply Chain Of Medicinal Products At Eu And Used For Preparation Of The Active Imp Tablets Are Masked By Over Encapsulation With Hard Gelatine Capsule 1 X 400 Mg In A Capsule To Maintain Blinding Matching Placebo Imp Capsule Are Prepared Containing Microcrystalline Cellulose1
- Clinical Pathway With Fasttrack1
- Postoperative Usual Protocol1
- Moxifloxacin1
Active Sponsors
- Hospital Universitario Virgen de la Arrixaca1
- Kuopio University Hospital1
- Seinajoki Central Hospital1
- Mikkeli Central Hospital1
- Pori Central Hospital1
Top Investigators
Turku University Hospital Professor of surgery
Hospital Universitario Virgen de la Arrixaca